Key Points He feels it's a clear buy at the current price. In his view, sotagliflozin has excellent potential to win FDA approval for a new indication. 10 stocks we like better than Lexicon Pharmaceuticals › An analyst's rather bullish initiation of coverage shone a light on Lexicon Pharmaceuticals (NASDAQ: LXRX) stock on Monday. Investors clearly took notice of this, as they piled into the company's stock to send it to a gain of nearly 6% on the day. A heartening evaluation Before market open, Cantor Fitzgerald prognosticator Steve Seedhouse flagged Lexicon as an overweight (buy, in other words) at a price target of $8 per share. That's more than four times the stock's current level of $1.90. Missed AI’s "Act 1"? Act 2 Could Be 15x Bigger.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.